Evidence map›Paper›PMID 40242440›Full record

ArticleFrontiers in pharmacology2025

Discovery of benzethonium chloride as a potent STAT3 inhibitor for the treatment of HNSCC.

Yuefeng Han, Shumin Li, Deshang Chen, Mingjie Zhang, Guoying Han, QianQian Xu, Xianming Ge, Mengli Wang, Yan Pan, Sien Ma and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuefeng Han *Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Shumin Li *Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Deshang ChenDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Mingjie ZhangDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Guoying HanDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
QianQian XuSchool of Pharmacy, Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine of IHM, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Xianming GeInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, China.
Mengli WangInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, China.
Yan PanInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, China.
Sien MaSchool of Pharmacy, Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine of IHM, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Beibei XuDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Mengmeng DengDepartment of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Bao ZhaoDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy with high mortality, and effective treatment strategies remain limited. This study investigated the effects of benzethonium chloride (BZN), an FDA-approved anti-infective agent, on HNSCC cell lines and its underlying mechanisms. BZN significantly inhibited the proliferation of HNSCC cell lines CAL27 and FaDu and induced apoptosis in both cell lines

Indexed as

apoptosisbenzethonium chloride (BZN)head and neck squamous cell carcinoma (HNSCC)Mcl-1stat3

Identifiers

PMID40242440
PMCPMC11999939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.